In: PD-(L)1 x VEGF bispecifics, Non-small cell lung cancer

RC148

RemeGen · AbbVie

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
9 active
10 in total
Targets
—
None known yet

What this is

How it works
A cancer drug that hits two targets at once: it releases a brake on the immune system (PD-1 or PD-L1) and starves the tumour of blood vessels (VEGF).PD-1/VEGF bispecific antibody
How it’s given
“The dose for Phase III will be determined based on Phase II results.”In the company’s words, NCT07935369 on ClinicalTrials.gov
Tested for
Non-Small Cell Lung Cancer (2 trials), Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Colorectal (Colon or Rectal) Cancer, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Breast Cancer, Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology, Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy, Solid Tumor
Main trialPhase 3
“This study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Participants will: Take RC148 or Tislelizumab combined with platinum-based chemotherapy until the end of the research.”In the company’s words, NCT07416474 on ClinicalTrials.gov

Coming up6

Changes2

Last 90 days

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 31 Dec 2027 RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Phase 3Recruiting Apr 2031 Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
Phase 2/3Recruiting 12 May 2027 A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
Phase 2/3Not yet recruiting 30 Apr 2030 RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
Phase 2Recruiting 1 Oct 2026 Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Phase 2Not yet recruiting Dec 2027 Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer
Phase 2Not yet recruiting Jul 2028 Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
Phase 1/2Recruiting 31 Dec 2025 A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Phase 1Active, not recruiting 31 Aug 2026 A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
Phase 1/2Unknown 28 Feb 2026 A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026

Follow RC148

Following is part of Solo: you see every change to RC148 the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in